



TABLE OF CONTENTS

<i>List of Tables</i>	<i>i</i>
<i>List of Figures</i>	<i>v</i>
<i>List of Abbreviations</i>	<i>ix</i>
<i>Materials and Equipments</i>	<i>xi</i>
1 INTRODUCTION	1
2 LITERATURE REVIEW	
2.1 Pain, neuropathic pain and drug delivery	13
2.2 Brain anatomy, physiology and barriers to drug delivery	16
2.3 Strategies for drug delivery to the brain	20
2.4 Receptor mediated transport through transferring receptors	28
2.5 Nanoparticles	32
2.6 Intranasal drug delivery	39
2.7 Microemulsion and Nanoemulsion	44
2.8 Drug profile	55
2.9 References	61
3 ANALYTICAL METHODS	71
3.1 Introduction	71
3.2 Methods	71
3.2.1 Estimation of Tramadol	71
3.2.1.1 Estimation of Tramadol in acetonitrile	72
3.2.1.2 Estimation of Tramadol in methanol	72
3.2.1.3 Estimation of Tramadol in PBS pH 5 with 2% Tween-80	72
3.2.1.4 Analytical method Validation	73
3.2.2 Estimation of Lamotrigine	74
3.2.2.1 Estimation of Lamotrigine in acetonitrile	74
3.2.2.2 Estimation of Lamotrigine in methanol	75
3.2.2.3 Estimation of Lamotrigine in PBS pH 5 with 1% SLS	75
3.2.2.4 Analytical method Validation	76
3.2.3 Estimation of residual PVA	77
3.2.4 Determination of proteins (Tf and Lf) by BCA method	78
3.3 Results and Discussion	80
3.3.1 Estimation of Tramadol	80
3.3.1.1 Calibration of Tramadol in acetonitrile	80

3.3.1.2	Calibration of Tramadol in methanol	82
3.3.1.3	Calibration of Tramadol in PBS pH 5 with 2% Tween-80	84
3.3.2	Estimation of Lamotrigine	87
3.3.2.1	Calibration of Lamotrigine in acetonitrile	87
3.3.2.2	Calibration of Lamotrigine in methanol	90
3.3.2.3	Calibration of Lamotrigine in PBS pH 5 with 1% SLS	92
3.3.3	Estimation of PVA	95
3.3.4	Estimation of Tf and Lf	96
3.4	Conclusion	97
3.5	References	98
4	PREPARATION, OPTIMIZATION AND CHARACTERIZATION OF CONJUGATED NANOPARTICLES	99
4.1	Introduction	101
4.2	Methods	101
4.2.1	Preparation and optimization of Nanoparticles	101
4.2.1.1	Preliminary optimization of various formulation parameters	101
4.2.1.2	Factorial design and optimization of formulation parameters	102
4.2.2	Transferrin and Lactoferrin conjugation of Nanoparticles	106
4.2.2.1	Conjugation procedure	107
4.2.2.2	Estimation of surface Transferrin/Lactoferrin density	107
4.2.2.3	Influence of amount of activating agent [Epoxy compound: SR-4GL]	107
4.2.2.4	Influence of amount of Transferrin and Lactoferrin	108
4.2.2.5	[¹ H]NMR of the Transferrin/Lactoferrin conjugated NPs	108
4.2.3	Lyophilization and optimization of lyoprotectant concentration	108
4.2.4	Characterization of Nanoparticles	108
4.2.4.1	Particle size and Zeta potential determination	109
4.2.4.2	Drug entrapment efficiency	110
4.2.4.3	Transmission electron microscopy	110
4.2.4.4	Differential Scanning Calorimetry	110
4.2.4.5	<i>In vitro</i> drug release	111
4.2.4.6	Estimation of residual PVA in Nanoparticles	111
4.3	Results and Discussion	112
4.3.1	Preparation and optimization of Nanoparticles	112
4.3.1.1	Preliminary optimization of various formulation parameters	112
4.3.1.2	Factorial design and optimization of Nanoparticles	113
4.3.2	Transferrin and Lactoferrin conjugation of Nanoparticles	129

4.3.3	Lyophilisation and optimization of cryoprotectant concentration	137
4.3.4	Characterization of Nanoparticles	140
4.4	Conclusion	147
4.5	References	148
5	PREPARATION, OPTIMIZATION AND CHARACTERIZATION OF MICROEMULSION AND NANOEMULSION	151
5.1	Introduction	151
5.2	Methods	153
5.2.1	Solubility determination	153
5.2.2	Preparation of drug solutions	153
5.2.3	Preparation and optimization of Microemulsion	153
5.2.3.1	Construction of phase diagram	153
5.2.3.2	Preparation of Microemulsion	154
5.2.3.3	Optimization of Microemulsion	154
5.2.4	Preparation and optimization of Nanoemulsion	154
5.2.4.1	Preparation of Nanoemulsion	155
5.2.4.2	Optimization of Nanoemulsion	155
5.2.5	Characterization of Microemulsion and Nanoemulsion	155
5.2.5.1	Appearance	156
5.2.5.2	Globule size and Zeta potential determination	156
5.2.5.3	Transmission Electron microscopy (TEM)	157
5.2.5.4	Estimation of drug in Microemulsion and Nanoemulsion	157
5.2.5.5	pH Determination	157
5.2.5.6	Viscosity Determination	157
5.2.5.7	Transmittance	157
5.2.5.8	<i>In vitro</i> drug diffusion study	157
5.2.6	Nasal toxicity study	161
5.3	Results and Discussion	162
5.3.1	Solubility study of Tramadol and Lamotrigine	162
5.3.2	Formulation of Tramadol and Lamotrigine Microemulsions	164
5.3.3	Formulation of Tramadol and Lamotrigine nanoemulsions	169
5.3.3.1	Optimization of Tramadol Nanoemulsion	169
5.3.3.2	Optimization of Lamotrigine nanoemulsion	170
5.3.4	Characterization of Microemulsion and Nanoemulsion	172
5.4	Conclusion	180
5.5	References	181
6	STABILITY STUDIES	183
6.1	Introduction	183
6.2	Methods	184

6.2.1	Stability study of Nanoparticles	184
6.2.2	Stability study of Microemulsion and Nanoemulsion	185
6.2.2.1	Accelerated physical stability study	185
6.2.2.2	Long term stability study	185
6.2.3	Statistical analysis and data interpretation	186
6.3	Results and Discussion	186
6.3.1	Stability study of Nanoparticles	186
6.3.2	Stability study of Microemulsion and Nanoemulsion	192
6.4	Conclusion	197
6.5	References	198
7	RADIOLABELING OF FORMULATIONS	199
7.1	Introduction	199
7.2	Methods	201
7.2.1	Radiolabeling of Drug solution and Nanoparticles	201
7.2.2	Radiolabeling of Microemulsion and Nanoemulsion	203
7.3	Results and Discussion	204
7.3.1	Nanoparticles	204
7.3.2	Microemulsion and Nanoemulsion	209
7.4	Conclusion	213
7.5	References	214
8	PHARMACOKINETICS AND BIODISTRIBUTION STUDIES	215
8.1	Introduction	215
8.2	Methods	215
8.2.1	Animals	215
8.2.2	Pharmacokinetics and Biodistribution Studies of Nanoparticles formulations	215
8.2.3	Pharmacokinetics and Biodistribution Studies of Microemulsion and Nanoemulsion formulations	217
8.2.4	Statistical Analysis	219
8.3	Result and Discussion	219
8.3.1	Pharmacokinetics and Biodistribution studies of Nanoparticles formulation	219
8.3.2	Pharmacokinetics and Biodistribution studies of Microemulsion and Nanoemulsion	233
8.4	Conclusion	244
8.5	References	246
9	PHARMACODYNAMIC STUDIES	249
9.1	Introduction	249

9.2	Methods	249
9.2.1	Antinociceptive Testing for Tramadol formulations	249
9.2.1.1	Animals	250
9.2.1.2	Evaluation of antinociceptive effect	250
9.2.1.3	Statistical Analysis	251
9.2.2	Antinociceptive Testing for Lamotrigine formulations	251
9.2.2.1	Animals	251
9.2.2.2	Evaluation of antinociceptive effect	251
9.2.2.3	Statistical Analysis	252
9.3	Results and Discussion	253
9.3.1	Antinociceptive Testing for Tramadol formulations	253
9.3.2	Antinociceptive Testing for Lamotrigine formulations	256
9.4	Conclusion	261
9.5	References	262
10	SUMMARY AND CONCLUSIONS	263